Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2024-10-09 Regulatory Filings
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
Regulatory Filings Classification · 1% confidence The document is a press release dated October 9, 2024, announcing the validation of a new investigator-initiated Phase 2 clinical study (PHAGOSCARPA) for PHAXIAM Therapeutics' phage therapy. It details the study design, endpoints, sponsorship (AP-HP), and expected timelines, including regulatory validation by ANSM. This type of announcement, focusing on clinical trial progress and strategic updates, is characteristic of an Investor Presentation (IP) or a general press release regarding R&D pipeline progress. Since it is a detailed announcement about a specific clinical development, it fits best under Investor Presentation (IP) which often covers pipeline updates, or potentially Regulatory Filings (RNS) if it were a mandatory filing. Given the content is a detailed update intended for investors about a specific clinical trial advancement, IP is the most appropriate specific category, as it is more detailed than a simple Earnings Release (ER) and not a formal regulatory form like 10-K or AR. It is not a report itself, but an announcement of R&D progress.
2024-10-09 English
PHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024
Earnings Release Classification · 1% confidence The document explicitly states it is publishing the 'résultats financiers du premier semestre 2024' (financial results for the first half of 2024). It contains a detailed financial table summarizing key figures for S1 2024 vs S1 2023, discusses operational expenses, net result, and cash position as of June 30, 2024. This content strongly aligns with an Interim/Quarterly Report (IR). Although it also mentions management changes (MANG) and provides a link to a webinar (CT/RPA), the primary focus and bulk of the content is the comprehensive financial performance review for the six-month period, making 'IR' the most appropriate classification. Furthermore, the text confirms the full financial statements were filed with the AMF on the same day, indicating this is the comprehensive report release, not just a brief announcement (RPA). H1 2024
2024-09-25 French
PHAXIAM Provides Business and Financial Update For the First Half of 2024
Interim / Quarterly Report Classification · 1% confidence The document is a press release titled 'PHAXIAM Provides Business and Financial Update For the First Half of 2024'. It contains a summary of business highlights, clinical trial progress, and a table of key financial figures (revenues, operating expenses, net loss, cash position) for the first half of 2024. While it references that the full financial statements were filed with the AMF, the document itself provides the substantive financial data and management analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report (IR). H1 2024
2024-09-25 English
PHAXIAM : RAPPORT FINANCIER SEMESTRIEL
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for the period ending June 30, 2024. It contains a management report, consolidated interim financial statements, notes to the financial statements, and a declaration by the responsible person. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-09-25 French
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils et déclaration d'intention (article L. 233-7 du code de commerce)" and details the crossing of ownership thresholds (5%, 10%, 15%, 20%, 25%) by Bpifrance in PHAXIAM THERAPEUTICS, along with a declaration of future intentions regarding the company. This type of mandatory filing in France, concerning changes in significant shareholdings and associated intentions, directly corresponds to the definition of Major Shareholding Notification (MRQ) in many regulatory contexts, although the specific French legal reference (L. 233-7) is key. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the most appropriate fit for a filing detailing the crossing of ownership thresholds by a major shareholder.
2024-07-04 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 1er juillet 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 1er juillet 2024" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of July 1, 2024). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF), which mandates monthly disclosure of total voting rights and share capital. This type of periodic disclosure regarding share capital structure and voting rights is a specific regulatory requirement. While it is a regulatory filing, the specific nature points towards a disclosure related to capital structure changes or voting rights updates. Reviewing the definitions, none perfectly match a routine monthly voting rights disclosure, but it is a formal regulatory announcement. It is not an AGM, 10-K, ER, or IR. It details changes in the total number of shares and voting rights, which is related to capital structure (SHA) or general regulatory reporting (RNS). Since it is a mandatory, periodic disclosure of voting rights and capital structure updates, and not a major event like a share issue (SHA) or a director's dealing (DIRS), the most appropriate general regulatory category is RNS, as it is a standard regulatory filing that doesn't fit the more specific categories like DIV, DIRS, or SHA (which usually implies a specific transaction announcement rather than a routine count). However, given the content focuses entirely on the total number of shares and voting rights, it is a very specific type of capital/shareholder information. Since there is no specific code for 'Monthly Voting Rights Disclosure', RNS (Regulatory Filings) serves as the best fit for a mandatory, periodic regulatory report that doesn't match the other specific types.
2024-07-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.